Syremis Therapeutics
Novel Therapies for Neuropsychiatric Conditions
Company Overview
Snapshot
Founded in April 2025 by Elisabeth Kogan, Elena Kagan, and Menashe Levy, Syremis Therapeutics operates with 11–50 employees. The company has raised $165 million across one funding round from 6 investors, with Dexcel Pharma and Third Rock Ventures identified as lead investors. In December 2025, Syremis Therapeutics launched with its significant Series A funding to develop best-in-class medicines for mental health conditions.
Business overview
Syremis Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel medicines for neuropsychiatric conditions. The company's pipeline targets mental health treatments through emerging and clinically validated mechanisms, including muscarinic M1/M4 agonism and next-generation NMDA antagonism. Syremis Therapeutics operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving the healthcare and life sciences markets.
Strategic signal
In December 2025, Syremis Therapeutics officially launched with a substantial $165 million Series A funding round. This launch and significant capital infusion signal strong investor confidence in the company's approach to addressing severe mental illnesses like schizophrenia, validating its clinical-stage pipeline and strategic focus on novel mechanisms such as muscarinic M1/M4 agonism and next-generation NMDA antagonism. For investors, this indicates a well-capitalized new entrant poised to advance its therapeutic candidates in a critical and underserved area of healthcare.
Log in to access full profile ›Company Intelligence Q&A
- When was Syremis Therapeutics founded?
- Syremis Therapeutics was founded in April 2025.
- What is Syremis Therapeutics' primary focus?
- Syremis Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines for neuropsychiatric conditions, focusing on mental health treatments.
- How much capital has Syremis Therapeutics raised to date?
- Syremis Therapeutics has raised a total of $165 million across one funding round.
- Which investors participated in Syremis Therapeutics' Series A funding round?
- In December 2025, Syremis Therapeutics secured its Series A funding with.
- What mechanisms does Syremis Therapeutics' neuropsychiatric pipeline target?
- Syremis Therapeutics' neuropsychiatric pipeline is rooted in emerging and clinically validated mechanisms, including muscarinic M1/M4 agonism and next-generation NMDA antagonism.